Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile
Ronak H. Mistry, DO

@rmistry91

🩸Hematologist @pennmedicine | 🎧Co-Host @thefellowoncall | ✈️🏋️‍♂️🌮 | 🎓Via @vumc_cancer @impennsy @RowanVirtuaSOM @DrewUniversity | Views My Own

ID: 42084590

linkhttp://www.TheFellowOnCall.com calendar_today23-05-2009 19:40:55

9,9K Tweet

1,1K Followers

1,1K Following

Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile Photo

My account has just become a Philadelphia Eagles and Philadelphia fan page lately, but what can I say? There’s no place quite like this and I’m just so happy to call this city home 🦅

Bread & Butter Haematology (@morphologyamigo) 's Twitter Profile Photo

Lupus Anticoagulant Testing Made Easy👇👇 No matter how much anyone explained this in training i still had a hard time remembering it With this Chart👇- Not so Much now 😀 #medtwitter #hematology #meded #medicine #blooducation

Lupus Anticoagulant Testing Made Easy👇👇
No matter how much anyone explained this in training i still had a hard time remembering it 
With this Chart👇- Not so Much now 😀
#medtwitter #hematology #meded #medicine #blooducation
Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile Photo

Even 8 years later, I still get all the feels on #MatchDay Congratulations to all future colleagues participating in #Match2025!

Even 8 years later, I still get all the feels on #MatchDay

Congratulations to all future colleagues participating in #Match2025!
Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile Photo

Excited to share that we will be presenting two #MedEd abstracts at ASCO 2025, including 1 poster (1st author) and 1 oral presentation (senior author)! TY to the Scientific Program Committee; the site coordinators; and all the study participants. See y’all in Chicago!

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

BREAKING from <a href="/NEJM/">NEJM</a> 
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
ASH (@ash_hematology) 's Twitter Profile Photo

The shortage of classical hematologists is growing. The ASH Ambassador Program is working to change that by identifying and inspiring learners early in their careers. Become an ASH Ambassador and close the gap: ow.ly/VCI950VwIuO #Hematology Leslie Ellis

Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile Photo

Teamwork makes the dream work and we really do have the best crew at Penn Medicine Hematology! Kicked off this morning with a surprise bridal shower for our amazing inpatient NP, Tara!

Teamwork makes the dream work and we really do have the best crew at <a href="/PennMedicine/">Penn Medicine</a> Hematology! 

Kicked off this morning with a surprise bridal shower for our amazing inpatient NP, Tara!
The Fellow On Call (@thefellowoncall) 's Twitter Profile Photo

This week, we round out our #APLS discussion talking all about management! What is the best anticoagulation? Also listen in as Daniel Hausrath and Vivek Patel, MD debate it out about when the optimal time to perform APLS testing is! Link in bio!

This week, we round out our #APLS discussion talking all about management! What is the best anticoagulation? 

Also listen in as <a href="/DanielHausrath/">Daniel Hausrath</a> and <a href="/vpatelmd/">Vivek Patel, MD</a> debate it out about when the optimal time to perform APLS testing is!

Link in bio!
The Fellow On Call (@thefellowoncall) 's Twitter Profile Photo

Our own Vivek Patel, MD and Ronak H. Mistry, DO are at #ASCO25 soaking in all the latest and greatest in #oncology and #meded! In addition, they’ll be presenting data from their innovative #meded research studies! Oral presentation # 9001: TODAY (5/31) Poster presentation # 9030: MONDAY (6/2)

Our own <a href="/vpatelmd/">Vivek Patel, MD</a> and <a href="/rmistry91/">Ronak H. Mistry, DO</a> are at #ASCO25 soaking in all the latest and greatest in #oncology and #meded! In addition, they’ll be presenting data from their innovative #meded research studies! 
Oral presentation # 9001: TODAY (5/31)
Poster presentation # 9030: MONDAY (6/2)
TwoOncDocs (@twooncdocs) 's Twitter Profile Photo

Our wonderful The Fellow On Call colleague Dr. Vivek Patel presenting final results from our multicenter randomized PODCAST-HOF trial And hot off the press today, publication in JCO: ascopubs.org/doi/pdfdirect/… #ASCO25

Our wonderful <a href="/TheFellowOnCall/">The Fellow On Call</a> colleague Dr. Vivek Patel presenting final results from our multicenter randomized PODCAST-HOF trial 

And hot off the press today, publication in JCO:

ascopubs.org/doi/pdfdirect/…

#ASCO25
The Fellow On Call (@thefellowoncall) 's Twitter Profile Photo

🚨Hot off the press: A simultaneous publication in JCO Oncology Practice alongside Vivek Patel, MD’s presentation highlighting the 1st cluster randomized study evaluating podcasts for heme/onc education! The outcome: The Fellow On Call and TwoOncDocs should be included for h/o fellow education!

🚨Hot off the press: A simultaneous publication in <a href="/JCOOP_ASCO/">JCO Oncology Practice</a> alongside <a href="/vpatelmd/">Vivek Patel, MD</a>’s presentation highlighting the 1st cluster randomized study evaluating podcasts for heme/onc education! 

The outcome: <a href="/TheFellowOnCall/">The Fellow On Call</a> and <a href="/TwoOncDocs/">TwoOncDocs</a> should be included for h/o fellow education!
Ronak H. Mistry, DO (@rmistry91) 's Twitter Profile Photo

So proud of this study and honored to be the senior author! What we’ve learned: The Fellow On Call and TwoOncDocs should be integrated into our heme/onc fellow education! 🔥 Link to this study: ascopubs.org/doi/10.1200/OP…